GANCICLOVIR AND MYCOPHENOLATE
No clinically significant pharmacokinetic interaction appears to occur between ganciclovir and mycophenolate. However, the manufacturers say that in renal impairment there may be competition for tubular secretion and increased concentra- tions of both drugs may occur. There are reports of neutropenia in patients taking mycophenolate with ganciclovir.
No action is needed, but increased monitoring may be prudent in patients with reduced renal function. Both mycophenolate mofetil and ganciclovir and its prodrug, valganciclovir, have the potential to cause neutropenia and leucopenia, therefore patients should be closely monitored for additive toxicity.
No action is needed, but increased monitoring may be prudent in patients with reduced renal function. Both mycophenolate mofetil and ganciclovir and its prodrug, valganciclovir, have the potential to cause neutropenia and leucopenia, therefore patients should be closely monitored for additive toxicity.